Biohaven announces positive results in their study of Troriluzole for Spinocerebellar ataxia (SCA)
On September 23rd, 2024, the pharmaceutical company Biohaven announced positive topline results from their study of the drug Troriluzole to treat SCAs 1,2,3,6,7,8 and 10. Those with SCA who […]